Filer Snapshot

TAKEDA PHARMACEUTICAL CO LTD

CIK 0001395064. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

107

Latest filing

06 Jul 2026

Industry

Pharmaceutical Preparations

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13F-HR for Q3 2025. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open 13F portfolio Save page

Largest parsed holding

OVID

$9.79M reported value

Open holding

13D/G large stake

OVID

08 Dec 2025 · 12% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Forms 3/4/5

4 filed on 06 Jul 2026 for CIK 0001395064.

View source filing
Listed symbols
TAK on NYSE
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Parsed SEC ownership coverage

These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.

13F portfolio$16.37M

Quarterly institutional holdings reported on Form 13F; not total AUM.

Forms 3/4/5 positions$119.8M

Reporting-owner positions with enough filing detail to estimate value.

Latest reported 13F value

13F
$16.37M

Reported market value from the latest parsed Form 13F information table; this is not total assets under management.

Source: SEC Form 13FScope: U.S.-listed equity holdings

Forms 3/4/5 position value

3/4/5
$119.8M

Estimated from parsed Forms 3/4/5 when filings include enough share and price data.

Source: Forms 3/4/5Confidence: Estimated when price data is available

Largest 13F holdings

13F
OVID EQ XLO STTK LYEL
+3 moreAMWL RANI LAB

Largest symbols in the latest parsed Form 13F information table.

Freshness: Latest parsed 13F period

Largest linked holdings

Largest issuer positions linked to this CIK across parsed 13F, 13D/G, and Forms 3/4/5 records.

DAWN PHAT OVID THRX XLO

Largest 13F holdings

Largest symbols in the latest parsed Form 13F information table.

OVID EQ XLO STTK LYEL AMWL RANI LAB

Largest active 13D stakes

Active large-stake positions disclosed in parsed Schedule 13D filings.

HLVX

Largest active 13G stakes

Passive or institutional large-stake positions disclosed in parsed Schedule 13G filings.

OVID
How to read these SEC ownership signals
  • Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
  • Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
  • Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 2 identity fields
SEC industry group
Pharmaceutical Preparations (Office of Life Sciences)
Business address
1 1, Nihonbashi Honcho 2 Chome, Chuo Ku, Tokyo, Japan, 103-8668

Filer intelligence

What SEC filings say about TAKEDA PHARMACEUTICAL CO LTD

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Open 13F portfolio Save filer

Quick read

  • Latest parsed 13F shows $16.37M across 8 reported holdings for Q3 2025.
  • Largest parsed 13F holding: OVID at $9.79M.
  • 2 recent 13D/G stake rows found; top row is OVID at 12% ownership.
  • Forms 3/4/5 show insider context for DAWN worth $71.54M.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio 8 rows

Quarterly institutional portfolio holdings.

Open
13D/G stakes 2 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 5 rows

Officer, director, and 10% owner holdings or transactions.

Open

Top parsed 13F holdings

Visual share of the latest parsed 13F portfolio. Values are reported market value, not a recommendation.

Q3 2025 - 13 Nov 2025

Top 5 concentration

96%

Share of latest parsed 13F value represented by the visible holdings below.

Top 5 reported value

$15.77M

Compared with $16.37M total 13F value.

Top 5 net change

+$222.8K

Position-value change inside the visible top holdings only.

13F concentration map

A simple visual split of the latest parsed 13F portfolio.

Largest add: LYEL · Largest trim: HLVX

OVID EQ XLO STTK LYEL Other holdings

OVID

59.8%

Ovid Therapeutics, Inc.

$9.79M

EQ

15.9%

Equillium, Inc.

$2.61M

XLO

7.6%

Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics)

$1.24M

STTK

7.5%

Shattuck Labs, Inc.

$1.23M

LYEL

5.4%

Lyell Immunopharma, Inc.

$891.4K

13D/G large-stake context

OVID

08 Dec 2025 · Common Stock, par value $0.001 per share

12%
Issuer page 13D/G history

HLVX

17 Sep 2025 · Common Stock, par value $0.0001 per share

0%
Issuer page 13D/G history

Forms 3/4/5 insider context

DAWN

07 Dec 2021 · 10% owner

$71.54M
Issuer page Owner page

PHAT

24 Jan 2024 · 10% owner

$30.42M
Issuer page Owner page

OVID

08 Dec 2025 · 10% owner

$11.68M
Issuer page Owner page

THRX

12 Oct 2021 · 10% owner

$4.93M
Issuer page Owner page

Latest update

What changed recently for TAKEDA PHARMACEUTICAL CO LTD

Ownership report updated

Latest ownership report period: 08 Dec 2025. Open the source-backed page to inspect the fresh filing or facts context.

Update date

09 Dec 2025

Page type

Ownership filings

Latest period

08 Dec 2025

Ownership context was refreshed from SEC Forms 3/4/5 filed on 09 Dec 2025.

Open ownership filings Browse recent public updates

Benchmark Context

Benchmark context for this company

TAKEDA PHARMACEUTICAL CO LTD has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest ownership report period: 08 Dec 2025. That gives you a fresh baseline before you compare this company with peers.

  • Latest company facts filing date: 25 Jun 2025.
  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0001395064 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
107
First seen
07 May 2021
Latest filing
06 Jul 2026
Entity
Company

Observed form types

13F-HR 20-F 3 3/A 4 SCHEDULE 13D/A SCHEDULE 13G/A

CIK-linked evidence first

TAKEDA PHARMACEUTICAL CO LTD SEC filings TAKEDA PHARMACEUTICAL CO LTD 13F portfolio TAKEDA PHARMACEUTICAL CO LTD 13D/G history TAKEDA PHARMACEUTICAL CO LTD owner filings TAKEDA PHARMACEUTICAL CO LTD insider transactions Open SEC filing index

Industry context: Pharmaceutical Preparations.

Latest Filings

Showing the latest 12 of 107 SEC filings for TAKEDA PHARMACEUTICAL CO LTD.

Open full filing history
4

4 filing

Filing date
06 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
06 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
06 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
06 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
06 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
06 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
06 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
06 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
06 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
06 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
06 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
06 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .